267 related articles for article (PubMed ID: 26140741)
1. Multidisciplinary Treatment of Severe Osteogenesis Imperfecta: Functional Outcomes at Skeletal Maturity.
Montpetit K; Palomo T; Glorieux FH; Fassier F; Rauch F
Arch Phys Med Rehabil; 2015 Oct; 96(10):1834-9. PubMed ID: 26140741
[TBL] [Abstract][Full Text] [Related]
2. Osteogenesis imperfecta in childhood: impairment and disability. A prospective study with 4-year follow-up.
Engelbert RH; Uiterwaal CS; Gerver WJ; van der Net JJ; Pruijs HE; Helders PJ
Arch Phys Med Rehabil; 2004 May; 85(5):772-8. PubMed ID: 15129402
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up in osteogenesis imperfecta type VI.
Trejo P; Palomo T; Montpetit K; Fassier F; Sato A; Glorieux FH; Rauch F
Osteoporos Int; 2017 Oct; 28(10):2975-2983. PubMed ID: 28689307
[TBL] [Abstract][Full Text] [Related]
4. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
[TBL] [Abstract][Full Text] [Related]
5. Predicting ambulatory function at skeletal maturity in children with moderate to severe osteogenesis imperfecta.
Montpetit K; Lafrance ME; Glorieux FH; Fassier F; Hamdy R; Rauch F
Eur J Pediatr; 2021 Jan; 180(1):233-239. PubMed ID: 32719894
[TBL] [Abstract][Full Text] [Related]
6. Musculoskeletal functional outcomes in children with osteogenesis imperfecta: associations with disease severity and pamidronate therapy.
Sousa T; Bompadre V; White KK
J Pediatr Orthop; 2014 Jan; 34(1):118-22. PubMed ID: 23863411
[TBL] [Abstract][Full Text] [Related]
7. Cranial base pathology in pediatric osteogenesis imperfecta patients treated with bisphosphonates.
Arponen H; Vuorimies I; Haukka J; Valta H; Waltimo-Sirén J; Mäkitie O
J Neurosurg Pediatr; 2015 Mar; 15(3):313-20. PubMed ID: 25559924
[TBL] [Abstract][Full Text] [Related]
8. Osteogenesis imperfecta in childhood: impairment and disability.
Engelbert RH; van der Graaf Y; van Empelen R; Beemer FA; Helders PJ
Pediatrics; 1997 Feb; 99(2):E3. PubMed ID: 9099760
[TBL] [Abstract][Full Text] [Related]
9. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV.
Zeitlin L; Rauch F; Plotkin H; Glorieux FH
Pediatrics; 2003 May; 111(5 Pt 1):1030-6. PubMed ID: 12728084
[TBL] [Abstract][Full Text] [Related]
10. Osteogenesis imperfecta in childhood: perceived competence in relation to impairment and disability.
Engelbert RH; Gulmans VA; Uiterwaal CS; Helders PJ
Arch Phys Med Rehabil; 2001 Jul; 82(7):943-8. PubMed ID: 11441383
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Bisphosphonate Therapy in Osteogenesis Imperfecta.
Biggin A; Munns CF
Curr Osteoporos Rep; 2017 Oct; 15(5):412-418. PubMed ID: 28823022
[TBL] [Abstract][Full Text] [Related]
12. Scoliosis in osteogenesis imperfecta caused by COL1A1/COL1A2 mutations - genotype-phenotype correlations and effect of bisphosphonate treatment.
Sato A; Ouellet J; Muneta T; Glorieux FH; Rauch F
Bone; 2016 May; 86():53-7. PubMed ID: 26927310
[TBL] [Abstract][Full Text] [Related]
13. Cyclic bisphosphonate therapy reduces pain and improves physical functioning in children with osteogenesis imperfecta.
Garganta MD; Jaser SS; Lazow MA; Schoenecker JG; Cobry E; Hays SR; Simmons JH
BMC Musculoskelet Disord; 2018 Sep; 19(1):344. PubMed ID: 30249227
[TBL] [Abstract][Full Text] [Related]
14. Pain and quality of life of children and adolescents with osteogenesis imperfecta over a bisphosphonate treatment cycle.
Tsimicalis A; Boitor M; Ferland CE; Rauch F; Le May S; Carrier JI; Ngheim T; Bilodeau C
Eur J Pediatr; 2018 Jun; 177(6):891-902. PubMed ID: 29637375
[TBL] [Abstract][Full Text] [Related]
15. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
Land C; Rauch F; Travers R; Glorieux FH
Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
[TBL] [Abstract][Full Text] [Related]
16. Osteogenesis imperfecta: diagnosis and treatment.
Biggin A; Munns CF
Curr Osteoporos Rep; 2014 Sep; 12(3):279-88. PubMed ID: 24964776
[TBL] [Abstract][Full Text] [Related]
17. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
[TBL] [Abstract][Full Text] [Related]
18. Update on the evaluation and treatment of osteogenesis imperfecta.
Harrington J; Sochett E; Howard A
Pediatr Clin North Am; 2014 Dec; 61(6):1243-57. PubMed ID: 25439022
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonate Treatment and the Characteristics of Femoral Fractures in Children With Osteogenesis Imperfecta.
Vuorimies I; Mäyränpää MK; Valta H; Kröger H; Toiviainen-Salo S; Mäkitie O
J Clin Endocrinol Metab; 2017 Apr; 102(4):1333-1339. PubMed ID: 28323993
[TBL] [Abstract][Full Text] [Related]
20. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C
Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
